Next-Generation Multiple Myeloma Therapies Market to Reach USD 37.07 Billion by 2033, Driven by Accelerated Immunotherapy Approvals and Precision Medicine Advances - DataM Intelligence
Legend Biotech Corporation - American Depositary Shares (LEGN)
Company Research
Source: PR Newswire
AUSTIN, Texas and TOKYO, Nov. 4, 2025 /PRNewswire/ -- According to the latest analysis by DataM Intelligence, the Next-Generation Multiple Myeloma Therapies Market Size was valued at USD 22.03 billion in 2023, increased to USD 23.13 billion in 2024, and is projected to reach USD 37.07 billion by 2033, growing at a CAGR of 5.4% during the forecast period (2025–2033). The market growth is fueled by rapid regulatory approvals, expanding adoption of bispecific antibodies, and the increasing use of CAR T-cell therapies in relapsed and refractory multiple myeloma (RRMM). Recent National Comprehensive Cancer Network (NCCN) guideline updates have transformed the treatment landscape for multiple myeloma. Notably, Linvoseltamab (brand name Lynozyfic) was added as a preferred agent for RRMM following its accelerated approval by the U.S. FDA in July 2025. Clinical trial results demonstrated an overa
Show less
Read more
Impact Snapshot
Event Time:
LEGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEGN alerts
High impacting Legend Biotech Corporation - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
LEGN
News
- Legend Biotech (NASDAQ:LEGN) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Legend Biotech (NASDAQ:LEGN) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- William Blair Maintains Hold Rating on Legend Biotech (LEGN) Despite Carvykti Label Safety Concerns [Yahoo! Finance]Yahoo! Finance
- Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps UpPR Newswire
- Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps UpPR Newswire
LEGN
Sec Filings
- 11/17/25 - Form 144
- 11/12/25 - Form 6-K
- 11/5/25 - Form SCHEDULE
- LEGN's page on the SEC website